Shan Zhong

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Manish R. Patel, H. Burris, J. Frederick, 2019, Journal of Clinical Oncology.

The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy

Jinming Zhao, X. Niu, Qingchang Li, 2019, Scandinavian journal of immunology.

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

Jaegil Kim, G. Demetri, S. Grupp, 2022, Nature Communications.

A phase 1, open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with pembrolizumab in subjects with unresectable solid tumors (Keynote-603).

J. Frederick, D. Cho, T. Zaks, 2019, Journal of Global Oncology.